In yesterday's discussion about the effect of ibrutinib on hair-texture, the topic of ibrutinib dose reduction was mentioned ( healthunlocked.com/cllsuppo... ). There is an ASH abstract reporting very encouraging results from a pilot study assessing ibrutinib dose reduction:
Abstract 4307 A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia
Conclusions: Taken together, these data suggest that IBR doses as low as 140 mg/d are sufficient to fully occupy BTK and abrogate kinase function. As off-target effects of IBR are not thought to contribute to clinical efficacy in CLL, exploration of lower doses is warranted to reduce the incidence of troublesome side effects such as AF and bleeding, while preserving efficacy. Accordingly, a larger, more definitive trial with clinical endpoints of IBR at a dose of 140 mg/d following 2 cycles at 420 and 280 mg/d is planned.